Fintel reports that on December 9, 2025, Barclays initiated coverage of Phathom Pharmaceuticals (NasdaqGS:PHAT) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 54.03% Upside
As of December 6, 2025, the average one-year price target for Phathom Pharmaceuticals is $22.95/share. The forecasts range from a low of $12.12 to a high of $30.45. The average price target represents an increase of 54.03% from its latest reported closing price of $14.90 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Phathom Pharmaceuticals is 263MM, an increase of 79.00%. The projected annual non-GAAP EPS is -4.43.
What is the Fund Sentiment?
There are 264 funds or institutions reporting positions in Phathom Pharmaceuticals. This is an decrease of 7 owner(s) or 2.58% in the last quarter. Average portfolio weight of all funds dedicated to PHAT is 0.22%, an increase of 17.19%. Total shares owned by institutions increased in the last three months by 1.90% to 69,842K shares. 
The put/call ratio of PHAT is 0.03, indicating a bullish outlook.
What are Other Shareholders Doing?
Frazier Life Sciences Management holds 12,466K shares representing 17.52% ownership of the company. No change in the last quarter.
Medicxi Ventures Management holds 7,465K shares representing 10.49% ownership of the company. No change in the last quarter.
Millennium Management holds 5,081K shares representing 7.14% ownership of the company. In its prior filing, the firm reported owning 2,250K shares , representing an increase of 55.71%. The firm increased its portfolio allocation in PHAT by 144.93% over the last quarter.
Invesco holds 3,865K shares representing 5.43% ownership of the company. In its prior filing, the firm reported owning 4,140K shares , representing a decrease of 7.12%. The firm increased its portfolio allocation in PHAT by 6.14% over the last quarter.
Carlyle Group holds 3,497K shares representing 4.92% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
